产品中心
当前位置：首页>产品中心Anti-CTAG2/AF350
货号： bs-6807R-AF350 基本售价： 2980.0 元 规格： 100ul
产品信息
- 产品编号
- bs-6807R-AF350
- 英文名称
- Anti-CTAG2/AF350
- 中文名称
- AF350标记的肿瘤/睾丸抗原2抗体
- 别 名
- Autoimmunogenic cancer/testis antigen NY ESO 2; Autoimmunogenic cancer/testis antigen NY-ESO-2; CAMEL; Cancer/testis antigen 2; Cancer/testis antigen 6.2; CT 2; CT2; CT6.2; CTAG 2; CTAG2; CTAG2_HUMAN; CTL recognized antigen on melanoma; ESO 2; ESO2; L antigen family member 1; LAGE 1; LAGE 1a protein; LAGE 2b; LAGE-1; LAGE1; LAGE2b.
- 规格价格
- 100ul/2980元购买 大包装/询价
- 说 明 书
- 100ul
- 研究领域
- 肿瘤 免疫学 肿瘤细胞生物标志物
- 抗体来源
- Rabbit
- 克隆类型
- Polyclonal
- 交叉反应
- Human,
- 产品应用
- IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
- 分 子 量
- 23kDa
- 性 状
- Lyophilized or Liquid
- 浓 度
- 1mg/ml
- 免 疫 原
- KLH conjugated synthetic peptide derived from human CTAG2 (151-180aa)
- 亚 型
- IgG
- 纯化方法
- affinity purified by Protein A
- 储 存 液
- 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol
- 保存条件
- Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
- 产品介绍
- background:
Testis and very low level in placenta and in some uterus samples. Observed in 25-50% of tumor samples of melanomas, non-small-cell lung carcinomas, bladder, prostate and head and neck cancers.
Tissue Specificity:
Testis and very low level in placenta and in some uterus samples. Observed in 25-50% of tumor samples of melanomas, non-small-cell lung carcinomas, bladder, prostate and head and neck cancers.
Similarity:
Belongs to the CTAG family.
Database links:Entrez Gene: 30848 Human
Omim: 300396 Human
SwissProt: O75638 Human
Unigene: 87225 Human
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.